After founding the "Google for LLMs," You.com, Richard Socher's next company, Recursive AI, could automate AI research itself ...

For most companies, the honest answer is: nobody knows.

Infosecurity outlines key recommendations for CISOs and security teams to implement safeguards for AI-assisted coding ...

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Recursion Pharmaceuticals ...

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Recursion Pharmaceuticals (NasdaqGS:RXRX) reports its ...

Forbes contributors publish independent expert analyses and insights. John Sviokla covers GenAI/AI's impact on commerce and society. This voice experience is generated by AI. Learn more. This voice ...

Great. Thanks, everyone, for joining. My name is Scott Schoenhaus. I am the health care tech equity analyst here at KeyBanc. We're a pleasure to have Ben Taylor, CFO of Recursion for a fireside chat.

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the 11 most popular AI penny stocks to buy now. On February 25, Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) reported Q4 revenue of $35.5 million ...

Recursion Pharmaceuticals’ latest earnings call struck a cautiously optimistic tone as management highlighted its first AI-enabled clinical proof-of-concept, major cost cuts, and an extended cash ...

Data is not available at this time. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is ...

Short interest in Recursion Pharmaceuticals Inc (NASDAQ:RXRX) increased during the last reporting period, rising from 168.52M to 174.14M. This put 35.44% of the company's publicly available shares ...